Aviara Pharmaceuticals is a privately-held biopharmaceutical company focused on the development of small molecule pharmaceuticals to enhance the effectiveness of cell therapies and treat inflammatory diseases. Aviara is developing a portfolio of small-molecule integrin antagonists against a variety of targets involved in the modulation of cell therapies and inflammatory disease, such as minimal residual disease in cancer, cardiac stem cell transplant, dry eye disease and inflammatory bowel disease.
There is no investment information
No recent news or press coverage available for Aviara Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
